{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T04:57:33Z","timestamp":1784696253300,"version":"3.55.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T00:00:00Z","timestamp":1781395200000},"content-version":"am","delay-in-days":286,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["R01MH122301"],"award-info":[{"award-number":["R01MH122301"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA057979"],"award-info":[{"award-number":["R01DA057979"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jsatjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Use and Addiction Treatment"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.josat.2025.209739","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T11:22:44Z","timestamp":1749468164000},"page":"209739","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Association of state medicaid prescription cap policies with trajectories of buprenorphine use for opioid use disorder"],"prefix":"10.1016","volume":"176","author":[{"given":"Patience M.","family":"Dow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Landon D.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Roma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa I.","family":"Shireman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie M.","family":"Donohue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaclyn M.W.","family":"Hughto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.josat.2025.209739_bb0005","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.clinthera.2014.12.011","article-title":"Effects of eliminating drug caps on racial differences in antidepressant use among dual enrollees with diabetes and depression","volume":"37","author":"Adams","year":"2015","journal-title":"Clinical Therapeutics"},{"key":"10.1016\/j.josat.2025.209739_bb0010","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jsat.2018.01.010","article-title":"Do benefits restrictions limit Medicaid acceptance in addiction treatment? Results from a national study","volume":"87","author":"Andrews","year":"2018","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"1","key":"10.1016\/j.josat.2025.209739_bb0015","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.annemergmed.2012.01.035","article-title":"National study of barriers to timely primary care and emergency department utilization among Medicaid beneficiaries","volume":"60","author":"Cheung","year":"2012","journal-title":"Annals of Emergency Medicine"},{"issue":"1","key":"10.1016\/j.josat.2025.209739_bb0020","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1001\/jamapsychiatry.2022.3673","article-title":"Racial and ethnic disparities in buprenorphine treatment duration in the US","volume":"80","author":"Dong","year":"2023","journal-title":"JAMA Psychiatry"},{"issue":"25","key":"10.1016\/j.josat.2025.209739_bb0025","doi-asserted-by":"crossref","first-page":"567","DOI":"10.15585\/mmwr.mm7325a1","article-title":"Treatment for opioid use disorder: Population estimates \u2014 United States, 2022","volume":"73","author":"Dowell","year":"2024","journal-title":"MMWR. Morbidity and Mortality Weekly Report"},{"issue":"9","key":"10.1016\/j.josat.2025.209739_bb0030","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1037\/amp0000744","article-title":"Stigma and substance use disorders: A clinical, research, and advocacy agenda","volume":"75","author":"Earnshaw","year":"2020","journal-title":"The American Psychologist"},{"issue":"1","key":"10.1016\/j.josat.2025.209739_bb0035","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12939-024-02174-8","article-title":"Frontline perspectives on barriers to care for patients with California Medicaid: A qualitative study","volume":"23","author":"Faiz","year":"2024","journal-title":"International Journal for Equity in Health"},{"issue":"6","key":"10.1016\/j.josat.2025.209739_bb0040","doi-asserted-by":"crossref","first-page":"e211048","DOI":"10.1001\/jamahealthforum.2021.1048","article-title":"Association between Medicaid prescription drug limits and access to medications and health care use among young adults with disabilities","volume":"2","author":"Geiger","year":"2021","journal-title":"JAMA Health Forum"},{"issue":"1","key":"10.1016\/j.josat.2025.209739_bb0045","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/add.15998","article-title":"The association between buprenorphine treatment duration and mortality: A multi-site cohort study of people who discontinued treatment","volume":"118","author":"Glanz","year":"2023","journal-title":"Addiction"},{"issue":"12","key":"10.1016\/j.josat.2025.209739_bb0050","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1377\/hlthaff.2016.0623","article-title":"Survey highlights differences in Medicaid coverage for substance use treatment and opioid use disorder medications","volume":"35","author":"Grogan","year":"2016","journal-title":"Health Affairs (Millwood)"},{"issue":"3","key":"10.1016\/j.josat.2025.209739_bb0055","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s11414-013-9341-3","article-title":"Variation in use of buprenorphine and methadone treatment by racial, ethnic, and income characteristics of residential social areas in New York City","volume":"40","author":"Hansen","year":"2013","journal-title":"The Journal of Behavioral Health Services & Research"},{"issue":"6","key":"10.1016\/j.josat.2025.209739_bb0060","doi-asserted-by":"crossref","first-page":"E414","DOI":"10.1097\/ADM.0000000000000980","article-title":"Medicaid prescription cap policies: Another structural barrier to medication for opioid use disorder","volume":"16","author":"Hughto","year":"2022","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/j.josat.2025.209739_bb0065","series-title":"Presentation at the 2024 Northeast Medicaid research symposium","article-title":"Medicaid prescription cap policies and access to medications for opioid use disorder: A content analysis","author":"Hughto","year":"2024"},{"key":"10.1016\/j.josat.2025.209739_bb0070","unstructured":"Kaiser Family Foundation. State Medicaid prescription limits. Kaiser Family Foundation. Retrieved November 7, 2024a from https:\/\/www.kff.org\/other\/state-indicator\/state-medicaid-prescription-limits\/?currentTimeframe=0&sortModel=%7B%22colId%22:%22Location%22,%22sort%22:%22asc%22%7D."},{"key":"10.1016\/j.josat.2025.209739_bb0075","author":"Kaiser Family Foundation"},{"key":"10.1016\/j.josat.2025.209739_bb0080","doi-asserted-by":"crossref","first-page":"103786","DOI":"10.1016\/j.drugpo.2022.103786","article-title":"Has the treatment gap for opioid use disorder narrowed in the U.S.? A yearly assessment from 2010 to 2019","volume":"110","author":"Krawczyk","year":"2022","journal-title":"International Journal of Drug Policy"},{"key":"10.1016\/j.josat.2025.209739_bb0085","doi-asserted-by":"crossref","first-page":"109669","DOI":"10.1016\/j.drugalcdep.2022.109669","article-title":"Buprenorphine treatment episode duration, dosage, and concurrent prescribing of benzodiazepines and opioid analgesics: The effects of Medicaid prior authorization policies","volume":"241","author":"Landis","year":"2022","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.josat.2025.209739_bb0090","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12913-016-1258-0","article-title":"Medicaid prescription limits: Policy trends and comparative impact on utilization","volume":"16","author":"Lieberman","year":"2016","journal-title":"BMC Health Services Research"},{"issue":"3","key":"10.1016\/j.josat.2025.209739_bb0095","doi-asserted-by":"crossref","first-page":"A129","DOI":"10.1016\/j.jval.2015.03.751","article-title":"Trajectories of buprenorphine treatment and associated emergency department and inpatient use in a large Medicaid program","volume":"18","author":"Lo-Ciganic","year":"2015","journal-title":"Value in Health"},{"issue":"5","key":"10.1016\/j.josat.2025.209739_bb0100","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/add.13270","article-title":"Association between trajectories of buprenorphine treatment and emergency department and in-patient utilization","volume":"111","author":"Lo-Ciganic","year":"2016","journal-title":"Addiction"},{"issue":"5","key":"10.1016\/j.josat.2025.209739_bb0105","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1093\/fampra\/cmu053","article-title":"Organizational aspects of primary care related to avoidable hospitalization: A systematic review","volume":"31","author":"van Loenen","year":"2014","journal-title":"Family Practice"},{"issue":"6","key":"10.1016\/j.josat.2025.209739_bb0110","doi-asserted-by":"crossref","first-page":"e211249","DOI":"10.1001\/jamahealthforum.2021.1249","article-title":"Three decades of drug cap studies are enough","volume":"2","author":"Madden","year":"2021","journal-title":"JAMA Health Forum"},{"issue":"2","key":"10.1016\/j.josat.2025.209739_bb0115","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1001\/jama.2021.7374","article-title":"Use of medications for treatment of opioid use disorder among US Medicaid enrollees in 11 states, 2014\u20132018","volume":"326","author":"Medicaid Outcomes Distributed Research","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.josat.2025.209739_bb0120","doi-asserted-by":"crossref","first-page":"108706","DOI":"10.1016\/j.drugalcdep.2021.108706","article-title":"The intersection of gender and drug use-related stigma: A mixed methods systematic review and synthesis of the literature","volume":"223","author":"Meyers","year":"2021","journal-title":"Drug and Alcohol Dependence"},{"issue":"1","key":"10.1016\/j.josat.2025.209739_bb0125","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1146\/annurev-clinpsy-081122-012416","article-title":"Recent advances in group-based trajectory modeling for clinical research","volume":"20","author":"Nagin","year":"2024","journal-title":"Annual Review of Clinical Psychology"},{"issue":"7","key":"10.1016\/j.josat.2025.209739_bb0130","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1177\/0962280216673085","article-title":"Group-based multi-trajectory modeling","volume":"27","author":"Nagin","year":"2018","journal-title":"Statistical Methods in Medical Research"},{"key":"10.1016\/j.josat.2025.209739_bb0135","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1146\/annurev.clinpsy.121208.131413","article-title":"Group-based trajectory modeling in clinical research","volume":"6","author":"Nagin","year":"2010","journal-title":"Annual Review of Clinical Psychology"},{"key":"10.1016\/j.josat.2025.209739_bb0140","author":"National Academies of Sciences, Engineering, and Medicine"},{"key":"10.1016\/j.josat.2025.209739_bb0145","author":"National Quality Forum"},{"key":"10.1016\/j.josat.2025.209739_bb0150","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.2147\/CLEP.S265287","article-title":"Trajectory modelling techniques useful to epidemiological research: A comparative narrative review of approaches","volume":"12","author":"Nguena Nguefack","year":"2020","journal-title":"Clinical Epidemiology"},{"key":"10.1016\/j.josat.2025.209739_bb0155","author":"Orgera"},{"issue":"1","key":"10.1016\/j.josat.2025.209739_bb0160","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1186\/s12913-018-3213-8","article-title":"What are the effective elements in patient-centered and multimorbidity care? A scoping review","volume":"18","author":"Poitras","year":"2018","journal-title":"BMC Health Services Research"},{"issue":"4","key":"10.1016\/j.josat.2025.209739_bb0165","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.jemermed.2019.06.004","article-title":"Use of emergency departments for preventative care among adults in the United States: Estimates from the 2017 National Health Interview Survey","volume":"57","author":"Primm","year":"2019","journal-title":"The Journal of Emergency Medicine"},{"issue":"6","key":"10.1016\/j.josat.2025.209739_bb0170","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1037\/ort0000692","article-title":"Attitudes toward methadone treatment among Black\/African Americans: Implications for engagement and retention","volume":"93","author":"Rigg","year":"2023","journal-title":"The American Journal of Orthopsychiatry"},{"issue":"7","key":"10.1016\/j.josat.2025.209739_bb0175","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1097\/MLR.0000000000000727","article-title":"Patterns of buprenorphine-naloxone treatment for opioid use disorder in a multistate population","volume":"55","author":"Saloner","year":"2017","journal-title":"Medical Care"},{"key":"10.1016\/j.josat.2025.209739_bb0180","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jsat.2018.09.001","article-title":"Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees","volume":"95","author":"Samples","year":"2018","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"2","key":"10.1016\/j.josat.2025.209739_bb0185","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1515\/fhep-2014-0016","article-title":"Patient outcomes and cost effects of Medicaid formulary restrictions on antidepressants","volume":"17","author":"Seabury","year":"2014","journal-title":"Forum for Health Economics & Policy"},{"key":"10.1016\/j.josat.2025.209739_bb0190","doi-asserted-by":"crossref","first-page":"111293","DOI":"10.1016\/j.drugalcdep.2024.111293","article-title":"LatinX harm reduction capital, medication for opioid use disorder, and nonfatal overdose: A structural equation model analysis among people who use drugs in Massachusetts","volume":"259","author":"Shrestha","year":"2024","journal-title":"Drug and Alcohol Dependence"},{"issue":"9","key":"10.1016\/j.josat.2025.209739_bb0195","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1056\/NEJM198708273170906","article-title":"Payment restrictions for prescription drugs under Medicaid. Effects on therapy, cost, and equity","volume":"317","author":"Soumerai","year":"1987","journal-title":"The New England Journal of Medicine"},{"issue":"10","key":"10.1016\/j.josat.2025.209739_bb0200","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1056\/NEJM199409083311006","article-title":"Effects of a limiting Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia","volume":"331","author":"Soumerai","year":"1994","journal-title":"The New England Journal of Medicine"},{"issue":"15","key":"10.1016\/j.josat.2025.209739_bb0205","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1056\/NEJM199110103251505","article-title":"Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes","volume":"325","author":"Soumerai","year":"1991","journal-title":"The New England Journal of Medicine"},{"issue":"S2","key":"10.1016\/j.josat.2025.209739_bb0210","doi-asserted-by":"crossref","DOI":"10.1111\/1475-6773.14394","article-title":"Medicaid managed care restrictions on medications for the treatment of opioid use disorder","author":"Stewart","year":"2024","journal-title":"Health Services Research"},{"key":"10.1016\/j.josat.2025.209739_bb0215","author":"Substance Abuse and Mental Health Services Administration"},{"issue":"1","key":"10.1016\/j.josat.2025.209739_bb0220","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/10550887.2016.1100960","article-title":"Retention in medication-assisted treatment for opiate dependence: A systematic review","volume":"35","author":"Timko","year":"2016","journal-title":"Journal of Addictive Diseases"},{"issue":"12","key":"10.1016\/j.josat.2025.209739_bb0225","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1097\/QAD.0000000000001541","article-title":"Ten-year trends in antiretroviral therapy persistence among US Medicaid beneficiaries","volume":"31","author":"Youn","year":"2017","journal-title":"AIDS"},{"issue":"8","key":"10.1016\/j.josat.2025.209739_bb0230","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25382","article-title":"Trends in medication adherence in HIV patients in the US, 2001 to 2012: An observational cohort study","volume":"22","author":"Youn","year":"2019","journal-title":"Journal of the International AIDS Society"},{"issue":"2","key":"10.1016\/j.josat.2025.209739_bb0235","doi-asserted-by":"crossref","first-page":"787","DOI":"10.3390\/ijerph6020787","article-title":"Attitudes toward methadone among out-of-treatment minority injection drug users: Implications for health disparities","volume":"6","author":"Zaller","year":"2009","journal-title":"International Journal of Environmental Research and Public Health"},{"issue":"12","key":"10.1016\/j.josat.2025.209739_bb0240","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1377\/hlthaff.2017.0218","article-title":"The uninsured do not use the emergency department more-they use other care less","volume":"36","author":"Zhou","year":"2017","journal-title":"Health Affairs (Millwood)"}],"container-title":["Journal of Substance Use and Addiction Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875925001183?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875925001183?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T20:25:11Z","timestamp":1754425511000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949875925001183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":48,"alternative-id":["S2949875925001183"],"URL":"https:\/\/doi.org\/10.1016\/j.josat.2025.209739","relation":{},"ISSN":["2949-8759"],"issn-type":[{"value":"2949-8759","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of state medicaid prescription cap policies with trajectories of buprenorphine use for opioid use disorder","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Use and Addiction Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.josat.2025.209739","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"209739"}}